Aurora Cannabis (NYSE:ACB) had its price target cut by research analysts at CIBC from C$8.00 to C$7.00 in a report issued on Thursday, The Fly reports. The brokerage currently has an “underperform” rating on the stock.
Several other analysts have also recently weighed in on the stock. Zacks Investment Research cut shares of Aurora Cannabis from a “hold” rating to a “sell” rating in a report on Wednesday, September 8th. Jefferies Financial Group raised shares of Aurora Cannabis from an “underperform” rating to a “hold” rating and reduced their target price for the company from $7.49 to $6.78 in a report on Friday, September 3rd. Atb Cap Markets reaffirmed an “underperform” rating on shares of Aurora Cannabis in a report on Friday, July 23rd. Finally, Cantor Fitzgerald cut their price objective on shares of Aurora Cannabis from C$12.00 to C$8.30 and set a “neutral” rating on the stock in a report on Friday, September 17th. Eight research analysts have rated the stock with a sell rating and four have assigned a hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Sell” and a consensus price target of $6.78.
Shares of ACB opened at $5.95 on Thursday. The stock has a market capitalization of $1.18 billion, a PE ratio of -0.40 and a beta of 3.17. Aurora Cannabis has a 1 year low of $3.71 and a 1 year high of $18.98. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.95 and a current ratio of 5.88. The company’s 50-day simple moving average is $6.93 and its 200-day simple moving average is $8.17.
Aurora Cannabis Company Profile
Aurora Cannabis, Inc engages in the production, distribution and sale of cannabis products. It also produces and sells indoor cultivation systems and hemp related food products. The company was founded by Terry Booth and Steve Dobler on December 21, 2006 and is headquartered in Calgary, Canada.
Further Reading: Mutual funds are not immune from market timing
Receive News & Ratings for Aurora Cannabis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurora Cannabis and related companies with MarketBeat.com's FREE daily email newsletter.